Teleflex Announces European Market Clearance for its Innovative Vascular Access Catheter
LIMERICK, Pa.--(BUSINESS WIRE)--Jul 30, 2012--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical devices for critical care and surgery, has announced that its Semprus BioSciences subsidiary has been issued CE certification from its notified body, the DEKRA Certification Group of The Netherlands, to market the company's Nylus™ Peripherally Inserted Central Catheter (PICC) with Semprus Sustain™ technology to the European Union.
The Nylus PICC uses a long-lasting polymer designed to reduce the attachment of platelets and blood proteins at the surface of the medical device. This provides benefits to the patient, the caregiver and the health care system. The Nylus PICC has been shown to reduce platelet adhesion and thrombus accumulation through in vitro and animal testing. 1 "This clearance enables us to further advance a new standard of care in PICC catheters,” commented David L. Lucchino, Vice President of Semprus Technology, Strategic and Business Development of Teleflex. “Our novel technology, with its ability to work in blood products and long-term duration, holds great potential to reduce infection and thrombus-related complications for patients – while substantially decreasing associated healthcare costs.” About Teleflex Incorporated Teleflex is a leading global provider of specialty medical devices for a range of procedures in critical care and surgery. Our mission is to provide solutions that enable healthcare providers to improve outcomes and enhance patient and provider safety. Headquartered in Limerick, PA, Teleflex employs approximately 11,200 people worldwide and serves healthcare providers in more than 130 countries. Additional information about Teleflex can be obtained from the company's website at www.teleflex.com.
Forward-Looking Statements Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K.
Teleflex, Semprus BioSciences, Nylus, and Semprus Sustain Technology are trademarks or registered trademarks of Teleflex Incorporated or its affiliates. ©2012 Teleflex Incorporated. 2012-1189 References: 1. In vitro and in vivo data on file.CONTACT: Teleflex Incorporated Jake Elguicze Treasurer and Vice President, Investor Relations 610-948-2836 KEYWORD: UNITED STATES EUROPE NORTH AMERICA NETHERLANDS PENNSYLVANIA INDUSTRY KEYWORD: SURGERY HEALTH BIOTECHNOLOGY HOSPITALS MEDICAL DEVICES SOURCE: Teleflex Incorporated Copyright Business Wire 2012 PUB: 07/30/2012 05:00 PM/DISC: 07/30/2012 05:00 PM http://www.businesswire.com/news/home/20120730006079/